Summary
25.11 0.35(1.41%)05/13/2024
Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharmaceuticals Inc (MIRM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.75 | 3.11 | -0.19 | -3.32 | -13.73 | -1.82 | 0.00 | 95.91 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.88 | |
| Open | 26.54 | |
| High | 26.77 | |
| Low | 25.59 | |
| Volume | 180,013 | |
| Change | -0.46 | |
| Change % | -1.75 | |
| Avg Volume (20 Days) | 267,712 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 23.14 - 35.56 | |
| Price vs 52 Week High | -27.22% | |
| Price vs 52 Week Low | 11.84% | |
| Range | -2.49 | |
| Gap Up/Down | 0.19 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,167 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 54.71 | |
| Book Value | 1.8550 | |
| Earnings Per Share | -6.1180 | |
| EPS Estimate Current Quarter | -1.7300 | |
| EPS Estimate Next Quarter | -0.6400 | |
| EPS Estimate Current Year | -4.5800 | |
| EPS Estimate Next Year | -5.1400 | |
| Diluted EPS (TTM) | -6.1180 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -10.2993 | |
| Return on asset (TTM) | -0.5463 | |
| Return on equity (TTM) | -2.0236 | |
| Revenue TTM | 16,000,000 | |
| Revenue per share TTM | 0.5480 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.6221 | |
| Revenue Enterprise Value | 15.1624 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 30,638,200 | |
| Shares Float | 12,177,691 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.59 | |
| Institutions (%) | 78.93 | |
05/11 14:25 EST - Seeking Alpha
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - Leerink Partners Gavin Clark-Gartner - Evercore ISI Dae Gon Ha - Stifel Steven Seedhouse - Raymond James David Lebowitz - Citi Jon Wolleben - Citizens JMP Thomas Yip - H.C. Wainwright Operator Hello, and welcome to the Mirum Pharmaceuticals First Quarter 2024 Financial Results and Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - Leerink Partners Gavin Clark-Gartner - Evercore ISI Dae Gon Ha - Stifel Steven Seedhouse - Raymond James David Lebowitz - Citi Jon Wolleben - Citizens JMP Thomas Yip - H.C. Wainwright Operator Hello, and welcome to the Mirum Pharmaceuticals First Quarter 2024 Financial Results and Business Update.
05/09 12:50 EST - Zacks Investment Research
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.
03/15 10:36 EST - Zacks Investment Research
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
02/28 20:57 EST - Seeking Alpha
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
02/28 18:36 EST - Zacks Investment Research
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago.
01/23 12:46 EST - Zacks Investment Research
Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging.
Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging.
01/03 08:45 EST - Business Wire
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
12/19 12:47 EST - Zacks Investment Research
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
12/19 09:10 EST - Seeking Alpha
Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss
Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negative implications for Livmarli in other indications. Livmarli's strong start in ALGS and an incremental opportunity in PFIC put it in a good position for continued growth despite the increasing presence of Ipsen's Bylvay.
Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss
Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negative implications for Livmarli in other indications. Livmarli's strong start in ALGS and an incremental opportunity in PFIC put it in a good position for continued growth despite the increasing presence of Ipsen's Bylvay.
11/20 16:05 EST - Business Wire
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.
11/05 01:51 EST - Seeking Alpha
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrew McKibben - VP, IR and Finance Christopher Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head, R&D Eric Bjerkholt - CFO Conference Call Participants Josh Schimmer - Cantor Gavin Clark-Gartner - Evercore ISI Mani Foroohar - Leerink Partners David Lebowitz - Citigroup Brian Skorney - Robert W. Baird & Co. Ed Arce - H.C.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrew McKibben - VP, IR and Finance Christopher Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head, R&D Eric Bjerkholt - CFO Conference Call Participants Josh Schimmer - Cantor Gavin Clark-Gartner - Evercore ISI Mani Foroohar - Leerink Partners David Lebowitz - Citigroup Brian Skorney - Robert W. Baird & Co. Ed Arce - H.C.
10/27 08:45 EST - Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023.
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023.
10/11 16:52 EST - InvestorPlace
7 Small-Cap Stocks That Get the Nod from Wall Street
While enterprises with diminutive market capitalizations tend to be high-risk, high-reward ventures, you can shift the odds in your favor with small-cap stocks with buy ratings. Thanks to the nod from Wall Street experts, you can feel a little bit more comfortable with the speculative step that you're taking.
7 Small-Cap Stocks That Get the Nod from Wall Street
While enterprises with diminutive market capitalizations tend to be high-risk, high-reward ventures, you can shift the odds in your favor with small-cap stocks with buy ratings. Thanks to the nod from Wall Street experts, you can feel a little bit more comfortable with the speculative step that you're taking.
09/24 03:51 EST - Seeking Alpha
Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
Mirum Pharmaceuticals has two drugs, maralixibat and volixibat, targeting rare liver diseases involving cholestasis. The company's lead program, maralixibat, was approved for Alagille syndrome and has a busy data drop schedule for label expansions. Mirum's pipeline includes programs for PFIC, CTX, Biliary Atresia, and Adult Cholestasis, making it a proper liver disease franchise.
Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
Mirum Pharmaceuticals has two drugs, maralixibat and volixibat, targeting rare liver diseases involving cholestasis. The company's lead program, maralixibat, was approved for Alagille syndrome and has a busy data drop schedule for label expansions. Mirum's pipeline includes programs for PFIC, CTX, Biliary Atresia, and Adult Cholestasis, making it a proper liver disease franchise.
09/15 07:31 EST - Zacks Investment Research
Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?
Mirum Pharmaceuticals, Inc. (MIRM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?
Mirum Pharmaceuticals, Inc. (MIRM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
09/06 12:47 EST - Zacks Investment Research
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
08/05 11:42 EST - Seeking Alpha
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Officer Peter Radovich – Chief Operating Officer Pam Vig – Head-Research and Development Conference Call Participants Steve Seedhouse – Raymond James Mani Foroohar – SVB Leerink Thomas Yip – H.C. Wainwright Operator Good afternoon, and thank you all for joining.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Officer Peter Radovich – Chief Operating Officer Pam Vig – Head-Research and Development Conference Call Participants Steve Seedhouse – Raymond James Mani Foroohar – SVB Leerink Thomas Yip – H.C. Wainwright Operator Good afternoon, and thank you all for joining.
08/03 18:46 EST - Zacks Investment Research
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $0.84 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $0.84 per share a year ago.
07/09 11:01 EST - Seeking Alpha
Mirum: Must Watch Biotech On Release Of Results From EMBARK Study
Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with biliary atresia, are expected in the 2nd half of 2023. It is expected that the global Biliary Atresia market could grow to $1.69 billion by 2029. Results from two phase 2 studies, using volixibat for patients with primary biliary cholangitis and primary sclerosing cholangitis, are expected to be released in the 2nd half of 2023.
Mirum: Must Watch Biotech On Release Of Results From EMBARK Study
Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with biliary atresia, are expected in the 2nd half of 2023. It is expected that the global Biliary Atresia market could grow to $1.69 billion by 2029. Results from two phase 2 studies, using volixibat for patients with primary biliary cholangitis and primary sclerosing cholangitis, are expected to be released in the 2nd half of 2023.
06/07 08:30 EST - Business Wire
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress.
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress.